N1BI34:BVMF
Neurocrine Biosciences Bdr
R$40.04
0.00%
(0.00) 1D
Sep 4, 4:37:42 PM GMT-3 · BRL
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for N1BI34...
Mkt. cap
15.55B
Avg. vol.
194.00
Volume
0.00
52-wk high
R$45.78
52-wk low
R$31.51
Shares outstanding
101.65M
No. of employees
2K
Mkt. cap
15.55B
Avg. vol.
194.00
Volume
0.00
52-wk high
R$45.78
52-wk low
R$31.51
Shares outstanding
101.65M
No. of employees
2K
Profile
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
About Neurocrine Biosciences Bdr
CEOKevin C. Gorman
Employees2.5K
Founded1992
HeadquartersSan Diego, California, United States
SectorBiotechnology
Websiteneurocrine.com